Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Active, not recruiting Phase 1 Interventional

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
BI 770371, Pembrolizumab, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • Minneapolis, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)

NCT02794155
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HDV Insulin Lispro, Insulin LISPRO
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Corona, California • Los Angeles, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 31, 2026, 5:56 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Mosliciguat in PH-ILD

NCT06635850
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
Mosliciguat, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT01471210
View directory record Official record
Conditions
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions
Urelumab (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products

NCT04226690
View directory record Official record
Conditions
Pain
Interventions
Active CBD/THC Dose 1, Active CBD/THC Dose 2, matched placebo comparator
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 31, 2026, 5:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

NCT02932280
View directory record Official record
Conditions
Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
Interventions
Neratinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Not applicable Interventional

Emergency Department Safety Assessment and Follow-up Evaluation 2

NCT02453243
View directory record Official record
Conditions
Suicide
Interventions
Safety Planning, A Lean Implementation Strategy
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
14,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 31, 2026, 5:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

NCT04865133
View directory record Official record
Conditions
COVID-19 Infection, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 31, 2026, 5:56 PM EDT
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 5:56 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Control of Myopia Using Novel Spectacle Lens Designs

NCT03623074
View directory record Official record
Conditions
Juvenile Myopia
Interventions
Novel spectacle lens design, Spectacle lenses
Device
Lead sponsor
SightGlass Vision, Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
13
States / cities
Whittier, California • Longwood, Florida • Pensacola, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 5:56 PM EDT
Active, not recruiting Not applicable Interventional

Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant

NCT06699797
View directory record Official record
Conditions
Sensori-Neural Deafness, Sensorineural Hearing Loss, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Bilateral, Sensorineural Hearing Loss, Profound, Sensorineural Hearing Loss, Severe
Interventions
Acclaim Cochlear Implant
Device
Lead sponsor
Envoy Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Tucson, Arizona • Seal Beach, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

NCT02265913
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years and older
Enrollment
4,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

NCT06926660
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vicadrostat, Empagliflozin, Placebo matching vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Huntsville, Alabama • Anaheim, California • San Dimas, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00609674
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

NCT00791219
View directory record Official record
Conditions
Onychomycosis
Interventions
SUBA-itraconazole, Itraconazole, Placebo
Drug
Lead sponsor
Halcygen Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

NCT03120936
View directory record Official record
Conditions
Transgender Persons, Pre-Exposure Prophylaxis
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, PrEP support
Drug · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
Fremont, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

NCT00457392
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
erlotinib, sunitinib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
63
States / cities
Florence, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

NCT03215277
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

NCT05420012
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Josef Stehlik
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

NCT01290692
View directory record Official record
Conditions
Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
Interventions
TVI-Brain-1
Biological
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

NCT00372853
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
CP-675,206, SU011248
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Scottsdale, Arizona • New Brunswick, New Jersey • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 31, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

NCT01143181
View directory record Official record
Conditions
Double-stranded DNA Virus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 31, 2026, 5:56 PM EDT
Terminated Not applicable Interventional Results available

Pulsed Radiofrequency Energy to Treat Post-Bunionectomy Pain

NCT01694199
View directory record Official record
Conditions
Post-operative Pain
Interventions
Pulsed Radiofrequency Energy (PRFE), No Pulsed Radiofrequency Energy (PRFE)
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 31, 2026, 5:56 PM EDT
Recruiting Phase 2 Interventional

Bumetanide in Patients With Alzheimer's Disease

NCT06052163
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bumetanide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 31, 2026, 5:56 PM EDT